Story
Sanofi to Pay Regeneron Up to $8 Billion to Expand Dupixent Partnership
Summary
Sanofi will make a $1 billion upfront payment and up to $7 billion in milestones to add four new experimental antibodies to its successful collaboration with Regeneron, aiming to bolster its future drug pipeline.
French pharmaceutical giant Sanofi announced it will pay its U.S. partner Regeneron up to $8 billion to expand their highly successful drug development partnership. The deal, which includes a $1 billion upfront payment, adds four new experimental antibodies to the collaboration responsible for the blockbuster drug Dupixent.
Deal Structure and Financials
Under the terms of the expanded agreement, Sanofi will provide Regeneron with an immediate $1 billion payment, with an additional $7 billion contingent on achieving certain development, regulatory, and sales milestones. For the new assets, the companies will share costs and profits equally, though the existing profit-sharing terms for Dupixent remain unchanged.
The agreement outlines a clear division of responsibilities: Regeneron will lead research and development, while Sanofi will spearhead global commercialization efforts. The companies also noted they have settled previous litigation related to their collaboration. Additionally, Regeneron has an option to co-develop Sanofi's experimental drug lunsekimig following the completion of its late-stage trials.
Strategic Rationale and Market Reaction
AdSanofi described the deal as a crucial first step in rebuilding its drug pipeline ahead of Dupixent's eventual loss of patent protection. The four new antibodies target the same inflammatory immune signals as Dupixent but are designed for longer-lasting effects in the body, potentially treating conditions like eczema.
Investors reacted positively to the news, with Sanofi's shares rising 2% in early trading on Thursday, according to Reuters. Analysts at Jefferies noted that while the assets are early-stage, the expansion "should be viewed positively, as it signals the new CEO’s proactive focus on the most important yet addressable uncertainties investors face."
Context of the Partnership
The collaboration between Sanofi and Regeneron has been highly lucrative, driven by the success of Dupixent. The drug, which treats inflammatory conditions across nine approved indications, is currently used by more than 1.5 million patients globally. This expansion builds on a proven model of co-development that has already yielded a major commercial success.
Read next
More on Stocks
European Equity Rally Halted in Q3 by Surging Oil Prices, Barclays Reports
European stocks finished the third quarter largely unchanged, as rising energy prices capped gains and ended a period of outperformance, according to a new report from Barclays.
Goldman Sachs Adds Solaria, Straumann to European Conviction List in October Refresh
Goldman Sachs has updated its influential 'European Conviction List - Directors’ Cut,' adding four companies, including Spanish solar developer Solaria, while removing three others. The changes reflect the investment bank's latest high-conviction views on European equities.
Solar Demand Outlook Brightens as Power Prices Offset Costs, KB Securities Says
An analysis by KB Securities suggests the recent solar stock sell-off may be excessive, as surging electricity prices are poised to offset higher module costs and interest rates.
Zealand Pharma Stock Falls Over 11% on Obesity Drug's Side Effect Concerns
Shares of the Danish biotech firm fell sharply after Phase III trial data for its obesity drug, survodutide, revealed a high patient discontinuation rate due to side effects, overshadowing positive efficacy results.